-

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024.

Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET.

Lynelle Hoch, president, Cell Therapy Organization, and Wendy Short Bartie, senior vice president, U.S. Hematology and Oncology, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami Beach, Florida, on Thursday, March 14, 2024. They will answer questions about the company beginning at 8:30 a.m. ET.

Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Release Versions

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend...

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable......

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference...
Back to Newsroom